All News

Investigational bispecific antibody pumitamig achieved a 70% response rate and disease control in all evaluable patients with advanced NSCLC.

ASCO 2026 highlighted advances in pancreatic, breast, sarcoma, lung and prostate cancers that may reshape treatment.

A breast cancer survivor shares the discovery of a new kidney mass and details how she will be a smarter, more assertive patient if it is cancer.

Teen cancer survivor Brynn and friend Teddy created Soothe Note, a free app helping patients track symptoms and prepare for appointments.

FDA approved Cavhanza, a new nilotinib formulation for adults with Ph+ CML that may offer more flexible dosing and easier administration.

Iza-bren improved survival and delayed disease progression versus chemotherapy in previously treated metastatic triple-negative breast cancer.

A Lynch syndrome survivor shares essential prep tips, the importance of stomach cancer screening and how a mindset shift beats yearly scanxiety.

In a phase 3 study, Opdivo plus Yervoy did not improve overall survival when combined with chemotherapy for HER2-negative gastric or GEJ cancer.

Dr. John Marshall explains why biomarker testing should be done early in colorectal cancer to guide treatment and identify targeted therapies.

Exercise after colon cancer chemotherapy reduced recurrence risk, improved survival and quality of life, according to the CHALLENGE trial.

Triage Cancer's Beyond Diagnosis program provides free webinars, guidance, and support for parents living with metastatic cancer.

I thought I understood breast cancer, until a routine conversation at the pharmacy changed everything.

ASCO 2026: Telephone-based weight loss significantly improves physical function and mental health in patients with breast cancer patients who are overweight or obese.

A blood cancer survivor debunks the movie myth of a quick cure, exposing the harsh, lasting side effects that remain after ringing the bell.

Ivonescimab plus chemotherapy helped patients with advanced squamous NSCLC live longer than tislelizumab plus chemotherapy.

Giredestrant plus Afinitor improved disease control after later treatment and delayed chemotherapy in ER-positive, HER2-negative breast cancer.

Giredestrant plus Afinitor may help patients with metastatic breast cancer delay chemotherapy and stay on effective treatment longer.

Patients with cancer taking GLP-1 drugs alongside immunotherapy had better long-term survival and fewer immune-related side effects.

Study data shows Ibtrozi provides rapid symptom relief and stable brain health for patients with advanced ROS1-positive lung cancer.

Dr. Emily Podany links food deserts to aggressive breast cancer mutations and shorter survival, stressing the need for social determinant screening.

OPTIMA trial data at ASCO 2026 shows a 50-gene test helps patients with high-risk breast cancer avoid unnecessary and toxic chemotherapy treatments.

Dr. Paolo Tarantino discusses the importance of strategic sequencing and drug-specific prophylaxis to optimize ADC therapy in breast cancer.

KEYNOTE-522 trial data shows adding Keytruda to chemotherapy drastically improves long-term survival for high-risk, early-stage TNBC.

ASCO 2026: MajesTEC-9 trial shows Tecvayli cuts death risk by 40% and improves outcomes in relapsed/refractory multiple myeloma patients.

Mezigdomide, Kyprolis and dexamethasone cut progression risk by 52% in relapsed or refractory multiple myeloma.

Lifyorli plus Abraxane improved survival in platinum-resistant ovarian cancer regardless of prior taxane use, according to updated ROSELLA data.

Sac-TMT plus Keytruda helped patients with PD-L1–positive advanced NSCLC live longer without their cancer worsening and increased response rates versus Keytruda alone.

Patients with EGFR exon 20-positive NSCLC had longer progression-free survival with Zegfrovy than chemotherapy.